EClinicalMedicine (Jun 2023)

Metastatic renal cell carcinoma to the pancreas and other sites—a multicenter retrospective studyResearch in context

  • Cassandra Duarte,
  • Junxiao Hu,
  • Benoit Beuselinck,
  • Justine Panian,
  • Nicole Weise,
  • Nazli Dizman,
  • Katharine A. Collier,
  • Nityam Rathi,
  • Haoran Li,
  • Roy Elias,
  • Nieves Martinez-Chanza,
  • Tracy L. Rose,
  • Lauren C. Harshman,
  • Dharmesh Gopalakrishnan,
  • Ulka Vaishampayan,
  • Yousef Zakharia,
  • Vivek Narayan,
  • Benedito A. Carneiro,
  • Anthony Mega,
  • Nirmish Singla,
  • Cheryl Meguid,
  • Saby George,
  • James Brugarolas,
  • Neeraj Agarwal,
  • Amir Mortazavi,
  • Sumanta Pal,
  • Rana R. McKay,
  • Elaine T. Lam

Journal volume & issue
Vol. 60
p. 102018

Abstract

Read online

Summary: Background: Metastatic renal cell carcinoma (mRCC) is a heterogenous disease with poor 5-year overall survival (OS) at 14%. Patients with mRCC to endocrine organs historically have prolonged OS. Pancreatic metastases are uncommon overall, with mRCC being the most common etiology of pancreatic metastases. In this study, we report the long-term outcomes of patients with mRCC to the pancreas in two separate cohorts. Methods: We performed a multicenter, international retrospective cohort study of patients with mRCC to the pancreas at 15 academic centers. Cohort 1 included 91 patients with oligometastatic disease to the pancreas. Cohort 2 included 229 patients with multiples organ sites of metastases including the pancreas. The primary endpoint for Cohorts 1 and 2 was median OS from time of metastatic disease in the pancreas until death or last follow up. Findings: In Cohort 1, the median OS (mOS) was 121 months with a median follow up time of 42 months. Patients who underwent surgical resection of oligometastatic disease had mOS of 100 months with a median follow-up time of 52.5 months. The mOS for patients treated with systemic therapy was not reached. In Cohort 2, the mOS was 90.77 months. Patients treated with first-line (1L) VEGFR therapy had mOS of 90.77 months; patients treated with IL immunotherapy (IO) had mOS of 92 months; patients on 1L combination VEGFR/IO had mOS of 74.9 months. Interpretations: This is the largest retrospective cohort of mRCC involving the pancreas. We confirmed the previously reported long-term outcomes in patients with oligometastatic pancreas disease and demonstrated prolonged survival in patients with multiple RCC metastases that included the pancreas. In this retrospective study with heterogeneous population treated over 2 decades, mOS was similar when stratified by first-line therapy. Future research will be needed to determine whether mRCC patients with pancreatic metastases require a different initial treatment strategy. Funding: Statistical analyses for this study were supported in part by the University of Colorado Cancer Center Support Grant from the NIH/NCI, P30CA046934-30.

Keywords